Theia Imaging is excited to announce a major milestone in our mission to bring advanced ophthalmic imaging to all: our next-generation Handheld OCT device – the Loris T2 – has officially been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).   This designation marks a pivotal moment not just for our team at Theia Imaging, but for the millions of pre-term infants born around the world each year who undergo screening for Retinopathy of Prem

The National Eye Institute of the National Institutes of Health has awarded Theia Imaging an SBIR Phase II Award of approximately $2.0M....

Theia is delighted to announce that we will be exhibiting at the ARVO 2024 Annual Meeting in Seattle. Come visit us at booth 1507 and...

Theia Imaging, a North Carolina-based MedTech startup developing cutting edge ophthalmic imaging devices, has been awarded a $1.9M SBIR...

Theia Imaging is thrilled to announce that we will be previewing an exciting new OCT device at the 2023 ARVO Annual Meeting in New...

Theia is delighted to announce that we will be exhibiting at the ARVO 2022 Annual Meeting in Denver, where we will be debuting our T1...